NTC strenghtens its position in Italy by introducing an aflibercept biosimilar, expanding treatment access for neovascular retinal diseases and its product portfolio.

NTC has obtained MDR certification for 20 medical devices, strengthening the value of its portfolio and safeguarding access to the European market.

In ten years, NTC has built a global presence with over 300 distributors in more than 100 countries, over 40 million units distributed each year, and team growth from less than 40 to 134 people, establishing itself as one of the leading European players in ophthalmic therapeutic solutions.

“By integrating therapies to treat glaucoma, we strengthen our commitment to patients who need safe and reliable long-term treatments. With our global partner network, we are ready to internationalize this offering,(…) NTC can act as a comprehensive reference partner for companies entering into ophthalmology or expanding existing portfolios”, stated Riccardo Carbucicchio, CEO of NTC.